Friday, 16 October 2026European Markets

CRCAM BRIE PIC2CCI And TINC Have A High Dividend Yield And Return On Equity In The Financial Services Sector.

Loading stream...

(vianews) - crcam brie pic2cci (crbp2.pa) is among this list of stock assets with the highest dividend rate and return on equity on the financial services sector.

financial asset price forward dividend yield return on equity
crcam brie pic2cci (crbp2.pa) €18.30 5.48% 4.04%
tinc (tinc.br) €12.10 4.52% 6.13%

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. crcam brie pic2cci (crbp2.pa)

5.48% forward dividend yield and 4.04% return on equity

caisse régionale de crédit agricole mutuel brie picardie société coopérative provides a range of banking and financial products and services to individuals, farmers, professionals, businesses, and local authorities. it offers savings support comprising monetary, bonds, and securities; and life insurance investments, as well as housing and consumer loans; payment services; and property and casualty insurance, provident insurance products, and life insurance products. the company is headquartered in amiens, france. caisse régionale de crédit agricole mutuel brie picardie société coopérative operates as a subsidiary of crédit agricole s.a.

earnings per share

as for profitability, crcam brie pic2cci has a trailing twelve months eps of €11.35.

pe ratio

crcam brie pic2cci has a trailing twelve months price to earnings ratio of 1.61. meaning, the purchaser of the share is investing €1.61 for every euro of annual earnings.

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 4.04%.

revenue growth

year-on-year quarterly revenue growth declined by 13.7%, now sitting on 640.29m for the twelve trailing months.

stock price classification

according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, crcam brie pic2cci's stock is considered to be overbought (>=80).

volume

today's last reported volume for crcam brie pic2cci is 1883 which is 53.9% below its average volume of 4085.

more news about crcam brie pic2cci.

2. tinc (tinc.br)

4.52% forward dividend yield and 6.13% return on equity

tinc comm. va is an investment firm specializing in investments in public and private infrastructure, real assets, and energy sector. tinc comm. va is based in antwerpen, belgium.

earnings per share

as for profitability, tinc has a trailing twelve months eps of €0.79.

pe ratio

tinc has a trailing twelve months price to earnings ratio of 15.32. meaning, the purchaser of the share is investing €15.32 for every euro of annual earnings.

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 6.13%.

yearly top and bottom value

tinc's stock is valued at €12.10 at 07:30 est, way under its 52-week high of €13.80 and above its 52-week low of €11.90.

dividend yield

as maintained by morningstar, inc., the next dividend payment is on oct 24, 2022, the estimated forward annual dividend rate is 0.54 and the estimated forward annual dividend yield is 4.52%.

more news about tinc.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com